Vivendy Therapeutics was founded in March 2006.

The company's mission is the development of an enzyme replacement therapy (ERT) for Morbus Morquio (Mucopolysaccharidosis - MPS IVA), a rare lysosomal storage disease (LSD). LSDs are inherited disorders caused by a deficiency of specific enzymes that are normally required for the breakdown of certain complex carbohydrates known as glycosaminoglycans (GAGs). Today, there is no therapy for MPS IVA in place, therefore the development of MPS IVA ERT adresses unmet medical needs with a high chance of success due to the fact that Vivendy is applying the established strategy of ERT.

Speaker Profile

Roland Toder, CEO

Roland Toder is CEO of Vivendy Therapeutics Ltd. Dr. Toder is also Senior Executive Partner of AKALPA; Toder & Partners in Lifesciences. He was CSO at GeneScan Europe AG and CEO of BioChip Technologies GmbH. He was actively involved in the successful IPO of GeneScan (2000) and also founded GeneScan Australia Pty Ltd (1999).

He studied Biology and gained his PhD in Human Genetics at the Albert Ludwigs University Freiburg; Germany (1994). Roland Toder worked as senior research fellow in Melbourne, Australia (1994-1997), returned to Germany and gained the „Habilitation“ and „venia legendi“ for Human Genetics at the Albert Ludwigs University (1999).